Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.6K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

6.1K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.1K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

2.8K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.8K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

961
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
961

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Glycemic Outcomes During the MiniMed<sup>TM</sup> Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes.

Diabetes technology & therapeutics·2023
Same author

Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor.

Diabetes technology & therapeutics·2023
Same author

Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial.

Diabetes technology & therapeutics·2022
Same author

Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.

Diabetes technology & therapeutics·2021
Same author

Initiating hybrid closed loop: A program evaluation of an educator-led Control-IQ follow-up at a large pediatric clinic.

Pediatric diabetes·2021
Same author

Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes.

Nature medicine·2020
Same journal

Continuous Glucose Monitoring Metrics and Perinatal Outcomes in Pregnant Women with Type 2 Diabetes.

Diabetes technology & therapeutics·2026
Same journal

Invited Commentary: Using Large Clinical Databases.

Diabetes technology & therapeutics·2026
Same journal

Impact of Technology Introduction on Glycemic Control of People Living with Type 1 Diabetes in Belgium: An Observational, Real-World Study.

Diabetes technology & therapeutics·2026
Same journal

Differences in Achieving Stringent Glycemic Targets Among Youth with Type 1 Diabetes: A SWEET Registry Study.

Diabetes technology & therapeutics·2026
Same journal

<i>Letter:</i> "Nocturnal Hypoglycemia: Characterization with Continuous Glucose Monitoring in a Real-World Setting".

Diabetes technology & therapeutics·2026
Same journal

Transient Benign Ketosis Is Common in Type 1 Diabetes During Very-Low Carbohydrate States: Novel Data from Continuous Ketone Sensor.

Diabetes technology & therapeutics·2026
See all related articles

Related Experiment Video

Updated: Apr 6, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Downloading Diabetes Device Information

H Peter Chase1, Susan L Owen1, Robert H Slover1

  • 1Barbara Davis Center for Childhood Diabetes, University of Colorado , Denver, Aurora, Colorado.

Diabetes Technology & Therapeutics
|August 4, 2015
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

8.7K
Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
08:16

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Published on: March 15, 2024

2.3K

Related Experiment Videos

Last Updated: Apr 6, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
Simple Continuous Glucose Monitoring in Freely Moving Mice
03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

8.7K
Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
08:16

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Published on: March 15, 2024

2.3K